Quarterly report · Q3

Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥434m2022-01-01 → 2022-09-30StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥542m2021-01-01 → 2021-09-30StandaloneNet sales
Operating income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOperating income
Operating income−¥851m2021-01-01 → 2021-09-30StandaloneOperating income
Ordinary income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥843m2021-01-01 → 2021-09-30StandaloneOrdinary income
Profit before tax−¥1.0bn2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Profit before tax−¥830m2021-01-01 → 2021-09-30StandaloneIncome before income taxes
Net income−¥1.0bn2022-01-01 → 2022-09-30StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥843m2021-01-01 → 2021-09-30StandaloneProfit loss
Total assets¥2.1bnat 2022-09-30StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.0bnat 2021-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥431mat 2022-09-30StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.7bnat 2022-09-30StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.4bnat 2021-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.6bnat 2022-09-30StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-23.872022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-20.942021-01-01 → 2021-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.772021-07-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio78.4%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.6%at 2021-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued45,979,100at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,305,500at 2021-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥358m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥916m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥681m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥328m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-09-30−¥757m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥523m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 325
ItemContextValueUnit
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)有 限 責 任 監 査 法 人 ト ー マ ツ
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)鈴  木  基  之
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)三  浦  靖  晃
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration_NonConsolidatedMember541690000JPY
Net sales (5-year summary)CurrentYTDDuration_NonConsolidatedMember433694000JPY
Net sales (5-year summary)Prior1YearDuration_NonConsolidatedMember712932000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-843016000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-1029779000JPY
Ordinary income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1329312000JPY
Net income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-842789000JPY
Net income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-1027559000JPY
Net income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-1479895000JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)CurrentYTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YearDuration_NonConsolidatedMember-JPY
Capital stock (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1472990000JPY
Capital stock (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1916611000JPY
Capital stock (5-year summary)Prior1YearInstant_NonConsolidatedMember1515929000JPY
Total number of issued shares (5-year summary)Prior1QuarterInstant_NonConsolidatedMember40305500
Total number of issued shares (5-year summary)CurrentQuarterInstant_NonConsolidatedMember45979100
Total number of issued shares (5-year summary)Prior1YearInstant_NonConsolidatedMember40781500
Net assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember2428442000JPY
Net assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember1650378000JPY
Net assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1893049000JPY
Total assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember2950471000JPY
Total assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember2081453000JPY
Total assets (5-year summary)Prior1YearInstant_NonConsolidatedMember2339439000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-20.94
Basic earnings loss per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-23.87
Basic earnings loss per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-36.74
Diluted earnings per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Equity to asset ratio (5-year summary)Prior1QuarterInstant_NonConsolidatedMember0.816
Equity to asset ratio (5-year summary)CurrentQuarterInstant_NonConsolidatedMember0.784
Equity to asset ratio (5-year summary)Prior1YearInstant_NonConsolidatedMember0.794
Basic earnings loss per share (5-year summary)Prior1QuarterDuration_NonConsolidatedMember-10.77
Basic earnings loss per share (5-year summary)CurrentQuarterDuration_NonConsolidatedMember-5.80
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember45979100
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember46205100
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant45979100
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant46205100
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass